# Prevention of Transmission of Hepatitis C Virus (HCV) From HCV-Viremic Organ Donor

> **NCT04596475** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of California, San Diego** · enrollment: 12 (actual)

## Conditions studied

- Hepatitis C
- Hepatitis C Virus Infection, Response to Therapy of

## Interventions

- **DRUG:** glecaprevir/pibrentasvir (GLE/PIB)

## Key facts

- **NCT ID:** NCT04596475
- **Lead sponsor:** University of California, San Diego
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-28
- **Primary completion:** 2022-04-21
- **Final completion:** 2022-04-21
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2022-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04596475

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04596475, "Prevention of Transmission of Hepatitis C Virus (HCV) From HCV-Viremic Organ Donor". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04596475. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*